Vanguard Capital Management’s Kailera Therapeutics KLRA Stock Holding History

Vanguard Capital Management’s Portfolio KLRA Stock Details KLRA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$37.3M	Buy	+1,693,958	New	+$37.2M	﹤0.01%	2102

Other funds holding KLRA

AVLSA

Atlas Venture Life Science Advisors Cambridge, Massachusetts $881M AUM 160.77% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

VFT

Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

Vanguard Capital Management's KLRA Position: Q2 2026 in Review

Vanguard Capital Management opened a new position in Kailera Therapeutics (KLRA) in Q2 2026: 1,693,958 shares worth $37.3M. The stake represents ﹤0.01% of the portfolio and ranks #2102 among its holdings.

47 funds tracked by Wall St. Rank hold KLRA as of Q2 2026.

Vanguard Capital Management held 1,693,958 shares of Kailera Therapeutics worth $37.3M as of Q2 2026.
Kailera Therapeutics was a new Vanguard Capital Management position in Q2 2026.
Kailera Therapeutics made up ﹤0.01% of Vanguard Capital Management's portfolio in Q2 2026, its #2102 holding.
47 funds tracked by Wall St. Rank held Kailera Therapeutics as of Q2 2026.

Based on Vanguard Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.